Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,247.30
+15.40 (1.25%)
Mar 9, 2026, 3:29 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 86.46B INR in the quarter ending December 31, 2025, with 8.36% growth. This brings the company's revenue in the last twelve months to 331.82B, up 7.31% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
331.82B
Revenue Growth
+7.31%
P/S Ratio
2.16
Revenue / Employee
11.98M
Employees
27,707
Market Cap
715.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cipla | 279.67B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 88.50B |
Aurobindo Pharma News
- 5 days ago - Aurobindo Pharma subsidiary launches Pomalidomide Capsules in US market, targets $3.3 billion opportunity - Business Upturn
- 7 days ago - Top stocks for trade today, March 2: Tata Motors, Hero MotoCorp, Zydus Lifesciences, Aurobindo Pharma, Vedanta and more - Business Upturn
- 10 days ago - Aurobindo Pharma subsidiary receives 4 observations after US FDA inspection at Telangana facility - Business Upturn
- 11 days ago - Pharma sector stocks today, Feb 26: Aurobindo Pharma surge 1.99%, Divis Lab up 1.51%, Zydus Life rises 1.26% - Business Upturn
- 18 days ago - Aurobindo Pharma faces Rs 169.83 crore GST demand - Business Upturn
- 21 days ago - Top stocks for trade today, Feb 16: Ola Electric, Aurobindo Pharma, Garden Reach, Torrent Pharma, NBCC and more - Business Upturn
- 27 days ago - Aurobindo Pharma Ltd (BOM:524804) Q3 2026 Earnings Call Highlights: Strong European Growth and ... - GuruFocus
- 27 days ago - Q3 2026 Aurobindo Pharma Ltd Earnings Call Transcript - GuruFocus